Livestock Vaccines Market Size & Share 2026-2035

Livestock Vaccines Market Size

The livestock vaccines market was valued at USD 6.71 billion in 2025, is projected to reach USD 7.23 billion in 2026, and is expected to grow at a 7.6% CAGR (2025–2035) to reach USD 14.01 billion by 2035.

The livestock vaccines market is shifting from outbreak-led purchasing toward more persistent preventive-health programs. Disease surveillance, public eradication campaigns, antimicrobial stewardship, and the economics of intensive animal production are increasing the strategic importance of vaccination, while advanced biologic platforms are changing the value mix of demand.

Livestock Vaccines Market Trends, Growth Drivers & GMI Forecast Outlook

Endemic transboundary disease risks and sovereign vaccination programs are creating a more dependable volume base, while recombinant and mRNA platforms raise the potential value per dose. The forecast depends on whether regulatory approvals, cold-chain investment, and public procurement systems can translate biological innovation into field-level coverage.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

HPAI's appearance across dairy cattle and additional livestock species changes the strategic case for vaccination beyond poultry-focused programs. A broader species exposure profile increases the relevance of adaptable antigen platforms, creates demand for regulatory-ready vaccine portfolios, and elevates the commercial value of preparedness even where routine vaccination has not yet been adopted.

FMD and PPR control campaigns provide a different demand mechanism: they convert national disease-control commitments into recurring tenders, supply agreements, and distribution requirements. These programs can support baseline demand through procurement cycles, but their commercial value is shaped by domestic manufacturing capacity, tender terms, delivery reliability, and the ability to sustain coverage in dispersed production systems.

Recombinant vectors are moving vaccination decisions toward products that can combine disease coverage with hatchery-compatible administration. Zoetis' European authorization for Poulvac Procerta HVT-ND demonstrates continued regulatory momentum for multivalent poultry biologics, while mRNA development programs could eventually broaden the premium platform opportunity in livestock health . Their adoption trajectory will depend on demonstrable field performance, manufacturing economics, and jurisdiction-specific authorization pathways.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Novel livestock biologics face a demanding investment cycle because formulation, safety, efficacy, manufacturing, and regulatory work must often be tailored by species and jurisdiction. Established multinational suppliers can distribute those fixed costs across broad portfolios and regulatory networks, whereas regional manufacturers may remain concentrated in conventional products or domestic tender markets.

Procurement-led demand can also restrain revenue quality. Public programs increase dose volumes, but centralized purchasing gives buyers substantial leverage over product specifications and prices. The resulting tension favors suppliers that can combine low-cost manufacturing, reliable batch availability, and locally credible distribution with differentiated technologies for private commercial systems.

Cold-chain execution remains a practical limit on realized demand. A vaccine program can be funded and doses can be distributed, yet protection may be undermined when storage, transport, and administration conditions are inconsistent. Thermostable formulations, portable refrigeration, and stronger last-mile veterinary infrastructure will determine whether high-need regions convert program ambition into sustained product use.

Livestock Vaccines Market Segment Analysis

By Animal Type

Poultry accounted for USD 2.41 billion in 2025 and represented 36% of the livestock vaccines market. The segment's scale reflects dense production systems and hatchery delivery models that support vaccination through in-ovo injection, spray, and drinking-water administration. Recurring disease-management needs across avian influenza, Newcastle disease, infectious bursal disease, and Marek's disease make flock health a core source of vaccine demand.

Cattle represented 28% of market revenue in 2025, equivalent to USD 1.88 billion. Demand is anchored by FMD programs in endemic markets and by respiratory and reproductive disease management in commercial dairy and beef systems. Higher-value injectable protocols, veterinary oversight, and the potential for broader HPAI preparedness reinforce cattle's role in the market's revenue mix.

Swine generated USD 1.20 billion in 2025 and accounted for 18% of market revenue. PRRS, porcine circovirus, Mycoplasma, and swine fever prevention support regular vaccination cycles, especially where herd turnover and disease-strain variation require protocol updates. Large-scale Asian production systems provide volume, while commercial farms in developed markets support demand for more specialized biologics.

Aquaculture generated USD 537 million in 2025 and is projected to expand at approximately 12% CAGR (2025–2035). The segment is benefiting from production density, export-oriented biosecurity requirements, and the need to reduce antibiotic dependence in farmed fish. Injectable multivalent vaccines are particularly relevant where survival rates, harvest quality, and disease-related losses have a direct effect on farm economics.

Sheep & goats generated USD 403 million in 2025 and accounted for 6% of market revenue. Demand is concentrated in FMD, PPR, clostridial disease, and small-ruminant health programs, particularly in regions where disease-control initiatives are integrated with food-security and rural-livelihood objectives. Delivery effectiveness and domestic production capacity remain critical to commercializing demand in these fragmented producer bases.

By Vaccine Type

Attenuated live vaccines generated USD 2.55 billion in 2025 and represented 38% of market revenue. Their position reflects cost-effective mass administration in poultry and the established role of live biologics in high-throughput flock-health programs. The segment remains commercially important, although biosafety expectations and the spread of injectable premium products may gradually alter its relative mix.

Inactivated vaccines represented 34% of market revenue in 2025 and generated USD 2.28 billion. Their durable position in ruminant and swine health is supported by conventional FMD, respiratory, and multivalent protocols where safety profiles, established manufacturing, and practical administration favor killed-antigen approaches.

Recombinant vaccines generated USD 1.07 billion in 2025 and are projected to grow at approximately 12.5% CAGR (2025–2035). Their commercial appeal stems from the ability to support multivalent protection and fit modern hatchery workflows, while also offering a pathway toward differentiated products in higher-value animal-health programs. Regulatory execution and production economics will determine how quickly recombinant products move from specialist use into broader livestock protocols.

Conjugate vaccines represented 7% of market revenue in 2025 and generated USD 470 million. They address bacterial disease settings where improved immune response can be commercially valuable, including selected swine, poultry, and cattle applications. Their opportunity is tied to pressure on producers to improve prevention practices where antimicrobial use is increasingly restricted or scrutinized.

By Route of Administration

Oral administration represented 46% of market revenue in 2025 and generated USD 3.08 billion. Its prominence is closely linked to poultry production, where drinking-water, feed, and spray-based delivery methods make broad flock coverage operationally feasible. The route's strength lies in throughput and labor efficiency rather than high value per administered dose.

Parenteral vaccines generated USD 2.82 billion in 2025 and represented 42% of market revenue. Injectable delivery supports cattle, swine, and premium poultry vaccine protocols that require more controlled dosing, complex formulations, or longer-duration immunity. This route is central to the market's premiumization because veterinary administration and product complexity can support higher-value treatment plans.

Other routes represented 12% of market revenue in 2025. Intranasal, ocular, and specialized hatchery delivery formats serve disease-prevention needs where local or mucosal immunity matters and where conventional oral or injectable protocols may not be optimal. Their relevance is tied to specific pathogen profiles and production-system practices.

By Application

Viral disease vaccines generated USD 3.49 billion in 2025 and represented 52% of market revenue. The category spans major livestock threats including HPAI, FMD, PPR, PRRS, and infectious poultry diseases. Persistent outbreak risk and government-backed eradication strategies make viral prevention the principal driver of vaccine deployment across both commercial and public channels.

Bacterial disease vaccines represented 32% of market revenue in 2025 and generated USD 2.14 billion. Demand is supported by the need to manage respiratory, enteric, and production-limiting bacterial conditions across poultry, cattle, swine, and small ruminants. Antimicrobial stewardship requirements strengthen the role of preventive vaccination where producers need compliant alternatives to routine drug-based control.

Parasitic vaccines represented 10% of market revenue in 2025 and generated USD 672 million. Coccidiosis prevention in commercial poultry is a key demand source, particularly where resistance concerns and production standards are making preventive biologics more attractive than continuous reliance on in-feed interventions.

By Distribution Channel

Veterinary hospital pharmacies represented 48% of market revenue in 2025 and generated USD 3.22 billion. The channel remains central for prescription biologics, injectable protocols, and veterinary-supervised herd-health programs. Its role is reinforced by the clinical advice, storage controls, and administration support required for many higher-value livestock products.

Retail channels represented 30% of market revenue in 2025 and generated USD 2.01 billion. They remain important for smaller producers and accessible over-the-counter categories, particularly where veterinary infrastructure is limited. However, stricter product controls and a growing emphasis on traceability can shift more complex biologics toward supervised channels.

E-commerce generated USD 873 million in 2025 and represented 13% of market revenue. Digital distribution can improve ordering convenience, visibility of product availability, and farm-level traceability when cold-chain capability is dependable. Its expansion will be shaped by the ability of platforms and distributors to meet handling requirements for temperature-sensitive biologics.

Livestock Vaccines Market Regional Analysis

North America Livestock Vaccines Market Analysis

North America generated USD 2.41 billion in 2025 and is projected to grow at a 6.5% CAGR (2025–2035). The Livestock Vaccines Market in the region is supported by biosecurity-intensive cattle, poultry, and swine operations; established veterinary channels; and reliable cold-chain infrastructure. HPAI preparedness has added urgency to disease surveillance and vaccine-development planning, while commercial producers continue to favor products that reduce production risk and support animal-health compliance.

United States

The United States generated USD 2.05 billion in 2025 and is projected to grow at a 6.8% CAGR (2025–2035). Its large commercial animal-production base and strong animal-health innovation ecosystem support demand across poultry, dairy, beef, and swine. Federal HPAI response activity has reinforced the importance of preparedness-oriented biologics and strengthened the strategic relevance of multi-species vaccine development ^{[1]U.S. Department of Agriculture (USDA). "USDA Announces $824 Million in New Funding to Protect Livestock Health; Launches Voluntary H5N1 Dairy Herd Status Pilot Program." usda.gov}.

Europe Livestock Vaccines Market Analysis

Europe generated USD 1.61 billion in 2025 and is projected to grow at a 5.8% CAGR (2025–2035). Mature production systems, prescription-oriented veterinary practices, and regulatory pressure to reduce antimicrobial use support sustained demand for preventive biologics. The region's opportunity is less dependent on herd expansion than on disease events, compliance requirements, and the replacement of conventional interventions with more targeted vaccine programs.

Germany

Germany represented 5.4% of global market revenue in 2025 and is projected to grow at a 5.5% CAGR (2025–2035). The country is an important operating base for animal-health manufacturers and serves large cattle and swine systems with demand for established and advanced biologics. Regional disease-management requirements and the country's organized veterinary infrastructure support uptake of premium prevention protocols.

United Kingdom

The United Kingdom generated USD 270 million in 2025 and is projected to grow at a 5.2% CAGR (2025–2035). Demand is supported by cattle and sheep production systems where veterinary-supervised injectable products are commercially relevant. Regulatory alignment, animal-health research activity, and producer interest in productivity-preserving disease prevention sustain the market's role as a specialized European demand center.

Asia Pacific Livestock Vaccines Market Analysis

Asia Pacific represented 26% of global market revenue in 2025 and is projected to grow at a 9.8% CAGR (2025–2035). Large livestock populations, endemic disease exposure, expanding aquaculture, and government-led immunization programs are the region's primary demand foundations. Its commercial trajectory depends on the execution of public procurement, domestic production capacity, and the gradual expansion of premium vaccine use beyond state-directed programs.

China

China generated USD 780 million in 2025 and is projected to grow at a 9.5% CAGR (2025–2035). Mandatory vaccination programs for diseases including HPAI and FMD create high-volume demand, while swine herd management supports recurring use of routine biologics. Domestic manufacturers are influential in cost-sensitive tender segments, creating a market in which multinational suppliers must differentiate through technology, specialized portfolio breadth, and channel positioning.

India

India generated USD 380 million in 2025 and is projected to grow at a 10.5% CAGR (2025–2035). The country's FMD-control agenda provides a substantial long-term demand catalyst by linking herd coverage targets to government procurement and veterinary delivery. Domestic manufacturers, including Indian Immunologicals, are strategically positioned because supply reliability, local manufacturing, and program alignment are essential to serving mass vaccination requirements ^{[2]Press Information Bureau, Government of India. "Ministry of Fisheries, Animal Husbandry & Dairying — FMD Vaccination Programme 2024." pib.gov.in}.

Latin America Livestock Vaccines Market Analysis

Latin America represented 9% of global market revenue in 2025 and is projected to grow at an 8.2% CAGR (2025–2035). Export-oriented beef, poultry, and swine systems create sustained incentives for FMD, respiratory disease, and biosecurity vaccination. The region combines multinational participation with strong domestic suppliers, particularly in ruminant biologics, and remains sensitive to importing-country health standards and government disease-control policies.

Middle East & Africa Livestock Vaccines Market Analysis

Middle East & Africa generated USD 336 million in 2025 and is projected to grow at a 10.1% CAGR (2025–2035). FMD, PPR, and other transboundary disease-control priorities are expanding the Livestock Vaccines Market's relevance to food security, productivity, and rural resilience. The region's potential is substantial, but demand realization depends on veterinary capacity, cold-chain execution, financing continuity, and the development of dependable local supply networks. WOAH has emphasized the importance of sustained animal-health investment in strengthening disease prevention and livestock-system resilience ^{[7]World Organisation for Animal Health (WOAH). "The State of the World's Animal Health 2026." woah.org}.

Livestock Vaccines Market Share & Competitive Landscape

The livestock vaccines market share is concentrated among multinational suppliers with broad species portfolios, regulatory capability, manufacturing depth, and established veterinary relationships. Merck Animal Health, Zoetis, and Boehringer Ingelheim Animal Health together held 52.8% of the market in 2025. Their scale provides an advantage in platforms that require substantial development investment and in serving commercial production systems across multiple geographies.

Merck Animal Health held 19.8% of the market in 2025. Its position is supported by a portfolio spanning poultry, cattle, swine, and aquaculture, allowing the company to address disease risk across diverse animal-production models. Its aquaculture presence broadens exposure to a segment where biosecurity and reduced antibiotic reliance are raising the value of preventive health programs.

Zoetis held 17.5% of the market in 2025. The company combines a large livestock commercial footprint with recombinant platform capabilities that are particularly relevant to poultry-health workflows. Its Poulvac Procerta range reflects how multivalent, hatchery-compatible products can strengthen competitive positioning in high-throughput production systems.

Boehringer Ingelheim Animal Health held 15.5% of the market in 2025. Its strengths in swine and poultry biologics, combined with a global manufacturing and distribution presence, position the company to compete in both conventional and next-generation product categories. Portfolio breadth is particularly important as producers seek disease-specific protocols without increasing operational complexity.

Ceva, HIPRA, Elanco, Virbac, Phibro Animal Health, Indian Immunologicals, Biogenesis Bago, Bioveta, Vaxxinova, Neogen, SAN VET, and Venkys contribute to a competitive market structure that varies by species, geography, and route to market. Mid-sized and regional suppliers can be highly competitive where local manufacturing, tender participation, veterinary-channel access, or specialized disease expertise is more important than global scale. Qualification barriers remain significant, particularly for advanced products, but local firms retain strategic relevance in government-backed programs and price-sensitive producer markets.

Recent Industry Developments

Zoetis received European Commission marketing authorization for Poulvac Procerta HVT-ND in July 2026. The recombinant vector vaccine is designed to protect chickens against Newcastle disease and Marek's disease through a single in-ovo or subcutaneous hatchery dose, reinforcing the commercial relevance of multivalent, hatchery-applied poultry vaccines in Europe .

Ceva Animal Health acquired Aquilon CyL S.L. in June 2026, strengthening its position in swine intestinal health. The transaction added a European commercial vaccine for swine dysentery caused by *Brachyspira hyodysenteriae*, expanding Ceva's preventive-biologics offering in a disease area where treatment options and antimicrobial stewardship are strategically consequential ^{[6]Ceva Animal Health. "Ceva Animal Health Acquires Aquilón Strengthening Its Leadership in Swine Intestinal Health." [ceva.com](http://ceva.com).}.